Serono Symposia International Foundation (SSIF) "Multiple Sclerosis: Future treatments and New Goals"

By Serono Symposia International Foundation, PRNE
Thursday, November 11, 2010

Vienna, Austria - November 12 -13, 2010

ROME, November 12, 2010 - Serono Symposia International Foundation has gathered a team
of leading international experts who will meet in Vienna on November 12th and
13th in order to discuss the future direction of multiple sclerosis therapy
during the event "Multiple Sclerosis (MS): future treatments and new goals".

The aim of the meeting is to provide participants with an
update on pharmacological targets, on the efficacy and safety of the new
generation of potential oral MS therapies, and to assess what may be
realistically achievable with these new treatments.

The meeting is divided into four sessions. The first three
sessions will cover the role of immune cells in MS and the challenges for
physicians associated with investigational oral therapies which may be
introduced in the next few years.

As Professor David Bates - Dept of Neurology Royal Victoria
Infirmary New Castle upon Tyne, UK and Scientific Organizer of the event -
said "The greatest challenge for experts in MS is to prevent the gradual
deterioration occurring after the initial inflammatory insult of the disease
and thereby stop the progressive phase of the disease itself. Current therapy
- added Professor Bates - is directed to reduce or stop inflammation and we
aim for an effective, non toxic, well tolerated therapy which is convenient
to take and safe in the long term".

The approach to MS is about to undergo substantial changes,
with the introduction of a number of compounds targeting a variety of
different aspects of the disease process; the treatment of Multiple
Sclerosis, therefore, is entering a new era with the introduction of
treatments that are characterized by novel mechanism of action, routes and
administration, dosages and markers of efficacy and safety. These new
compounds will not replace the ones already available, so far primary
"management tool" of the disease, but will be combined with them in complex
therapeutic protocols; this will offer innovative options for personalized
treatments, according to patient's and disease's characteristics.

Therefore, the final session of this scientific symposium - as
described by Professor Bates, will include a panel discussion in order to
stimulate debate about how patients management may change in the next few
years. "The most ambitious goal is for us all to achieve a status of "freedom
from disease activity"- ended Professor Bates.

"This important event reflects the long term commitment of
Serono Symposia International Foundation - said Jean-Daniel Baki, Board
Member and Secretary of the Board of Serono Symposia International
Foundation, to develop medical educationl programs on the hottest topics,
today, in MS. More deeply, in order to cover the medical educational need of
a wide range of physicians specialized in this disease".

Serono Symposia International Foundation is a non-profit
organization based in Geneva (Switzerland). It was founded to disseminate the
most innovative achievements and potential developments of medical and
scientific research through conferences, training courses, online courses and
publications. In particular, it provides Continuing Medical Education for
doctors and healthcare professionals by organizing high-level scientific
programs. Over the past four decades Serono Symposia International Foundation
has organized more than 1500 international scientific congresses and
published more than 500 proceedings with the most important international

Francesca Caputo, Serono Symposia International Foundation, Salita San Nicola da Tolentino 1/b, Rome, Italy, Ph: +39-06-420-413-568, E-mail: info at

will not be displayed